DOP2012000048A - Derivado de anillo heterocíclico fusionado y uso del mismo - Google Patents

Derivado de anillo heterocíclico fusionado y uso del mismo

Info

Publication number
DOP2012000048A
DOP2012000048A DO2012000048A DO2012000048A DOP2012000048A DO P2012000048 A DOP2012000048 A DO P2012000048A DO 2012000048 A DO2012000048 A DO 2012000048A DO 2012000048 A DO2012000048 A DO 2012000048A DO P2012000048 A DOP2012000048 A DO P2012000048A
Authority
DO
Dominican Republic
Prior art keywords
same
derivative
heterocyclic ring
fused heterocyclic
fused
Prior art date
Application number
DO2012000048A
Other languages
English (en)
Inventor
Satoshi Sasaki
Yuta Tanaka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43627972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000048(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of DOP2012000048A publication Critical patent/DOP2012000048A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE DESCRIBE UN DERIVA DE ANILLO HETEROCICLICO FUSIONADO QUE TIENE ACTIVIDAD DE INHIBICION SMO POTENTE, Y EL USO DEL DERIVADO DE ANILLO HETEROCICLICO FUSIONADO. SE DESCRIBEN EN FORMA ESPECIFICA UN COMPUESTO REPRESENTADO POR LA FORMA ESPECIFICA (CI) [EN DONDE CADA SIMBOLO ES TAL COMO SE DEFINE EN LA DESCRIPCION] O UNA SAL DEL MISMO; Y UN AGENTE MEDICINAL QUE COMPRENDE EL COMPUESTO O UN PROFARMACO DEL MISMO, EL CUAL SE PUEDE UTILIZAAR COMO UN INHIBIDOR SMO O UN AGENTE PROFILACTICO O TERAPEUTICO PARA CANCER.
DO2012000048A 2009-08-26 2012-02-22 Derivado de anillo heterocíclico fusionado y uso del mismo DOP2012000048A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009195770 2009-08-26
JP2010015644 2010-01-27

Publications (1)

Publication Number Publication Date
DOP2012000048A true DOP2012000048A (es) 2012-05-15

Family

ID=43627972

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000048A DOP2012000048A (es) 2009-08-26 2012-02-22 Derivado de anillo heterocíclico fusionado y uso del mismo

Country Status (24)

Country Link
US (1) US8907089B2 (es)
EP (1) EP2471790B1 (es)
JP (1) JP5599802B2 (es)
KR (1) KR20120078703A (es)
CN (1) CN102574851A (es)
AU (1) AU2010287492A1 (es)
BR (1) BR112012004134A2 (es)
CA (1) CA2771833A1 (es)
CL (1) CL2012000461A1 (es)
CR (1) CR20120095A (es)
DO (1) DOP2012000048A (es)
EA (1) EA201270311A1 (es)
EC (1) ECSP12011747A (es)
GE (1) GEP20146075B (es)
IL (1) IL218323A0 (es)
IN (1) IN2012DN02069A (es)
MA (1) MA33589B1 (es)
MX (1) MX2012002419A (es)
NZ (1) NZ598749A (es)
PE (1) PE20121326A1 (es)
SG (1) SG178504A1 (es)
TN (1) TN2012000084A1 (es)
WO (1) WO2011024872A1 (es)
ZA (1) ZA201201795B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471793B1 (en) * 2009-08-26 2016-10-05 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
JP6280573B2 (ja) 2013-03-14 2018-02-14 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ブロモドメイン阻害薬としてのフロピリジン

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
AU2001277731A1 (en) 2000-08-09 2002-02-18 Welfide Corporation Fused bicyclic amide compounds and medicinal use thereof
WO2003059884A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005081960A2 (en) 2004-02-25 2005-09-09 Wyeth Inhibitors of protein tyrosine phosphatase 1b
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2008057469A1 (en) * 2006-11-02 2008-05-15 Wyeth Small organic molecule regulators of cell proliferation
WO2008057468A1 (en) * 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
HUE030052T4 (en) 2007-06-29 2017-06-28 Pfizer Benzimidazole derivatives
RU2364597C1 (ru) 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
JP4685891B2 (ja) 2008-02-19 2011-05-18 株式会社ハネックス 分離装置
TWI480282B (zh) 2008-02-26 2015-04-11 Takeda Pharmaceutical 稠合雜環衍生物及其用途
JP2010015644A (ja) 2008-07-04 2010-01-21 Fujitsu Ltd スピンドル機構、電磁変換特性評価機、および情報記憶装置
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent

Also Published As

Publication number Publication date
CL2012000461A1 (es) 2012-10-05
EP2471790B1 (en) 2015-03-18
GEP20146075B (en) 2014-04-10
ZA201201795B (en) 2013-05-29
MX2012002419A (es) 2012-04-19
US20120220570A1 (en) 2012-08-30
JPWO2011024872A1 (ja) 2013-01-31
JP5599802B2 (ja) 2014-10-01
PE20121326A1 (es) 2012-10-11
AU2010287492A1 (en) 2012-03-29
CR20120095A (es) 2012-06-26
TN2012000084A1 (en) 2013-09-19
CA2771833A1 (en) 2011-03-03
EA201270311A1 (ru) 2012-09-28
MA33589B1 (fr) 2012-09-01
NZ598749A (en) 2013-01-25
EP2471790A1 (en) 2012-07-04
SG178504A1 (en) 2012-04-27
IN2012DN02069A (es) 2015-08-21
EP2471790A4 (en) 2013-07-31
IL218323A0 (en) 2012-04-30
CN102574851A (zh) 2012-07-11
ECSP12011747A (es) 2012-05-30
WO2011024872A1 (ja) 2011-03-03
KR20120078703A (ko) 2012-07-10
BR112012004134A2 (pt) 2017-06-20
US8907089B2 (en) 2014-12-09

Similar Documents

Publication Publication Date Title
CL2016002971A1 (es) Combinación.
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
CO7141410A2 (es) Compuesto heterocíclico nitrogenado
CL2016001737A1 (es) Derivados heterocíclicos bicíclicos como inhibidores de bromodominio
CL2015000829A1 (es) Inhibidores de histona desmetilasas
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CR20150337A (es) Derivados de pirimidinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
CO6680609A2 (es) Composición acuosa que contiene bromhexina
UA108618C2 (uk) Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CL2016000241A1 (es) Formulación de inhibidores de la syk.
CL2015002530A1 (es) Inhibidores de cdc7
CR20120448A (es) Compuesto heterocíclico
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
CL2011001811A1 (es) Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico.
CR20140108A (es) Compuesto de ciclopropanoamina
DOP2011000260A (es) Pirimidinas fusionadas
TWD161529S (zh) 治療燈
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
CL2015002060A1 (es) Compuestos.
CL2014000783A1 (es) Metodos para determinar si se necesita usar un farmaco depurador de nitrogeno o para determinar el incremento de una dosificacion del farmaco depurador de nitrogeno en un sujeto que recibe actualmente dicho farmaco; y uso del farmaco depurador de nitrogeno para el tratamiento de un trastorno de retencion de nitrogeno, tal como un trastorno del ciclo de urea y encefalopatia hepatica.
ES2570958T3 (es) Composición para el tratamiento de la fístula
CL2012003602A1 (es) Compuestos heterociclicos nitrogenados fusionados, moduladores de fosfodiesterasas; un medicamento; un método para prevenir o tratar la esquizofrenia; y su uso para la produccion de un agente para prevenir o tratar la esquizofrenia.
NI201500150A (es) TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas